PDCD1 and cancer: Based on one of the more substantial pan-cancer transcriptional analyses of ECM gene dysregulation, TGF-β activation in CAFs is a crucial indicator for ECM dysfunction in cancer and this CAF-driven ECM dysfunction is identified as a single important event responsible for the failure of PD-1 blockade cancer immunotherapy [61].